US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

enVVeno Medical Corporation - Common Stock (NQ:NVNO)

8.100 +0.060 (+0.75%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about enVVeno Medical Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe ® System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal study An... 
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spin Real answers to what investors need to know about enVVeno and why they need to know it... 
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
Access the video webcast here 
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
From enVVeno Medical Corporation
Via ACCESS Newswire
News headline image
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Via ACCESS Newswire
News headline image
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
Via ACCESS Newswire
News headline image
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
Via ACCESS Newswire
News headline image
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
Via ACCESS Newswire
News headline image
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
enVVeno Medical Announces Reverse Stock Split
Via ACCESS Newswire
News headline image
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
Via ACCESS Newswire
News headline image
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Via ACCESS Newswire
News headline image
enVVeno Medical Updates Regulatory Status of VenoValve(R)
Via ACCESS Newswire
News headline image
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
Via ACCESS Newswire
News headline image
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Via ACCESS Newswire
News headline image
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Via ACCESS Newswire
News headline image
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
Via ACCESS Newswire
News headline image
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Via ACCESS Newswire
News headline image
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
News headline image
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Via ACCESS Newswire
News headline image
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
Via ACCESS Newswire
< Previous 1 2 3 4 Next >